Vaxxas: A Needleless Way to Administer Vaccines With HD-MAP Technology

Vaxxas represents the next generation of vaccines, utilizing an innovative technology called HD-MAP. This technology has the potential to enhance the effectiveness of existing vaccines. By employing microprojections that penetrate the skin and reach the immune cells directly underneath, the vaccine components are able to quickly travel to the lymph nodes. The introduction of this new vaccination technique offers three key advantages: firstly, it eliminates the requirement for refrigeration, secondly, it is highly efficient in terms of dosage, and thirdly, it has the potential for self-administration.

Related article: Valneva’s Breakthrough Chikungunya Single-shot Vaccine: Release Phase 3 Data

Overcoming Vaccine refrigeration and Enabling Self-Administration 

The current need for refrigeration poses significant challenges for many vaccines, as they can lose effectiveness without proper cooling. This becomes particularly problematic when vaccines need to be transported to regions without electricity or where power outages frequently occur. Furthermore, a lack of trained personnel capable of administering vaccines correctly results in the underutilization of certain vaccines. Vaxxas addresses these issues by providing thermal stability for specific vaccines, rendering refrigeration unnecessary. Additionally, its needle-free administration makes self-administration a possibility.

Advancing Clinical Trials and Scaling up Production for Future Availability

Vaxxas is presently undergoing six clinical trials involving different vaccines. It is currently in Phase I of clinical trials for COVID-19 and influenza vaccines. The company has established a new facility to expand the production of HD-MAP vaccines and is actively preparing for the launch of its initial commercial products. Although they are not currently available for purchase, it is anticipated that they will be in the near future.

Author

GeneOnline Team